VIVUS to Present at the H.C. Wainwright 20th Annual Global Investment Conference on September 5, 2018
August 22 2018 - 7:30AM
VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a specialty
pharmaceutical company committed to the development and
commercialization of innovative therapies focusing on treatments
for patients with serious unmet medical needs, today announced that
John Amos, Chief Executive Officer, will present at the H.C.
Wainwright 20th Annual Global Investment Conference on Wednesday,
September 5, 2018 at 5:30 pm ET in New York City. Mr. Amos will
provide a corporate overview, review the Company’s clinical and
commercial product portfolio, and discuss the company’s strategies
for building a portfolio of cash flow-positive assets, reducing its
debt and moving toward sustained profitability.
An audio webcast of the presentation will be
available in the events and presentations section of the Company’s
investor relations website, or by clicking here.
About VIVUS
VIVUS is a biopharmaceutical company committed
to the development and commercialization of innovative therapies
that focus on advancing treatments for patients with serious unmet
medical needs. For more information about the Company, please visit
www.vivus.com.
Forward-Looking Statements
Certain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements may be identified
by the use of forward-looking words such as "anticipate,"
"believe," "forecast," "estimate," "expect," "intend," "likely,"
"may," "plan," "potential," "predict," "opportunity" and "should,"
among others. There are a number of factors that could cause actual
events to differ materially from those indicated by such
forward-looking statements. VIVUS does not undertake an
obligation to update or revise any forward-looking statements.
Investors should read the risk factors set forth
in VIVUS' Form 10-K for the year ended December 31,
2017 as filed on March 14, 2018, and as amended by the
Form 10-K/A filed on April 26, 2018, and periodic reports
filed with the Securities and Exchange Commission.
Contact: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
VIVUS,
Inc. |
|
|
|
|
|
|
Lazar
Partners |
Mark Oki |
|
|
|
|
|
|
David Carey |
Chief Financial
Officer |
|
|
|
|
|
|
dcarey@lazarpartners.com |
oki@vivus.com |
|
|
|
|
|
|
212-687-1768 |
650-934-5200 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
VIVUS (NASDAQ:VVUS)
Historical Stock Chart
From Mar 2024 to Apr 2024
VIVUS (NASDAQ:VVUS)
Historical Stock Chart
From Apr 2023 to Apr 2024